Abstract: The African American/Black population in the United States (US) is disproportionately affected by hepatitis C virus (HCV) and has lower response rates to current treatments. This analysis evaluates the participation of African American/Blacks in North American and European HCV clinical trials. The data source for this analysis was the PubMed database.
INTRODUCTION
A frican Americans are disproportionately affected by Hepatitis C Virus (HCV) in the United States. HCV infection is a leading cause of cirrhosis, hepatocellular carcinoma and is the most common indication for liver transplantation in the United States. 1 An estimated 3.2 million persons in the United States have chronic HCV infection and carry risk of severe morbidity and increased mortality. 2, 3 While African Americans comprise approximately 13% of the US population, they make up approximately 23% of Americans with hepatitis C. 4 A report using NHANES III data (1999e2002) found that the rate of a positive HCV antibody test was higher in blacks than in whites (3.2% versus 1.5%). Black men had higher rates of infection, and the highest prevalence rate was 9.8% among black men ages 40 to 49 years. 5, 6 HCV treatment is undergoing rapid evolution with the first generation protease inhibitors released in 2011 and now multiple direct acting antivirals regimens that re interferon free. 7, 8 Although the burden of HCV on African Americans is significant, this population has been traditionally underrepresented in clinical trials. Previous newmedicationshavebeenreleased withlimitedexperience in African Americans, and post-approval studies in the past have consistently demonstrated lower HCV treatment response rates among African Americans. [9] [10] [11] The purpose of this study was to review the participation of African Americans in HCV trials during the first decade of this millennium through the development of the first generation protease inhibitors.
METHODS

Literature Search
We performed the literature search in March 2012 using the PubMed search engine (US National Library of Medicine, National Institutes of Health, Bethesda, M.D., USA). With the dates of publication limited to between 2000 and 2011, we entered the following MeSH terms/supplementary concepts into the search: "Hepatitis C, Chronic," "interferon alfa-2a," and "interferon alfa-2b." The aforementioned terms were also searched for in titles and abstracts. Only the results of this search were further processed for data collection and analysis. The collection of results was not supplemented with other outside articles.
Data Collection
The PubMed search provided 588 search results, which were later screened for inclusion (see below). The results encompassed 132 different journals and 406 unique authors. The research team manually collected the results using a pre-designed data collection form. Year of publication, name of first author, and journal were used to identify results in the form. In addition, several other fields were created to itemize data collected from individual results. In addition to basic information, the following data were collected: "Genotypes studied," "HIV co-infection "Other medications used," "Race reported (Y/N)," "Total patients," "Number white," "Number black," "Number Latino," "Number Asian," and "Number other". Studies were designated as "reporting race" or "reporting ethnicity" if they included a statement or table explaining patient racial or ethnic makeup.
Inclusion criteria were English articles with participants aged older than 18 years with chronic HCV. Exclusion criteria were non-human studies, non-randomized trials, letters/case reports, cohort studies, articles not reporting outcomes of interest or primary data (editorials, reviews, secondary analyses), studies enrolling specific ethnic groups, studies specifically enrolling patients with significant secondary conditions (e.g. thalassemia, cryoglobulinemia, coagulation disorders, etc.), or studies not using interferon-alfa or PEG-interferon.
Definitions and Statistical Analysis
Given that multicenter studies were conducted in multiple countries and regions of the world, trial site designations were regional descriptions designated with the terms "partially" or "only". The regions of interest in this analysis were North America and Europe. "Partially" indicated that a particular region was at least one of the trial sites, while "only" indicates that there were no other regions among the trial sites. "Partially" data groups were much larger than "only" groups, and were also skewed towards the mean reporting statistics.
We obtained HCV prevalence data from Armstrong, et al., a large survey by the National Center for Health Statistics reporting HCV prevalence in the United States between 1999 and 2002. 4 We hypothesized that the expected rate of African Americans in the HCV therapy clinical trials should be equal to the relative burden of this disease among African Americans within the HCV population. Using the data from Armstrong, et al., we estimated that African Americans make up approximately 23% of people in the United States with hepatitis C. For this analysis, we selected the HCV trials that included only North American or Canadian subjects.
The proportions of African-American subjects in studies of hepatitis C were summarized using a random effects model because of the clear heterogeneity of the studies. 12 We used the method of DerSimonian and Laird 13 as implemented in Comprehensive Meta-Analysis. 14 The estimated proportion was 0.148 with 95 percent confidence limits of 0.126 to 0.174. As a sensitivity analysis we calculated estimates using two other models as implemented in the FAST*PRO software. 15, 16 The estimate for the empirical Bayes model was 0.145 (95 percent confidence interval of 0.118 to 0.175) and the estimate for the beta-binomial model was 0.158 (95 percent confidence interval of 0.130 to 0.188). All models clearly exclude the reported U.S. rate of 0.23.
RESULTS
Using the systematic review, 588 clinical trials on hepatitis C were originally identified. Of the 588 trials initially identified, 314 (53.4%) were randomized controlled trials ( Figure 1 
Reporting of Racial Data
Many of the trials that met search criteria did not include race or ethnicity when reporting results. Data on ethnicity was collected and reported less then racial data. Furthermore, when ethnicity was included, clear definitions for ethnicity were not apparent. Often, ethnicity was inappropriately used interchangeably with race. The data on ethnicity were also often incomplete for respective datasets (N not equal to 100). The lack of data on ethnicity combined with the inaccurate ethnic data that were reported made statistical analyses of the ethnicity of the clinical trials problematic.
Of the 314 RCT's that met search criteria, 123 (39.2%) reported race (Figure 1 ). The likelihood of race being reported at all within an RCT appeared to be impacted by where the RCT was conducted. North American trials reported race at a higher rate than European trials. 
DISCUSSION
The goal of this analysis was to evaluate the participation of African Americans/Blacks within HCV clinical trials. Of the 314 RCTs that met search criteria, only 123 (39.2%) reported race. The reasons for such low reporting of racial and ethnic data on study participants are unclear. One potential explanation may be related to the lack of consensus on how to collect and report these often selfreported racial and ethnic variables. The differences between racial reporting within the US and Europe are likely related to increased emphasis on racial disparities, specifically among African Americans, within the US. The reason for the increase in reporting of racial outcomes in Europe after 2005 is unclear. Interestingly, the FDA approved in June 2005 a combination medication of isosorbide dinitrate and hydralazine hydrochloride named BiDil®, which was the first drug approved by the agency to treat a disease in patients identified by race (heart failure in African Americans). 17 
18 This document made recommendations concerning the use of Office of Management and Budget (OMB) designations for collecting of racial and ethnic data in clinical trials.
Given the surprisingly low percentage of eligible RCTs that reported race at all, a standardized method of collecting and reporting racial and ethnic data should be considered. A standardized approach would help ensure consistent and accurate collection of this important information. While the US food and drug administration (FDA) has published recommendations on the collection of racial and ethnic data, this information is used as a guide and not considered a requirement. There is no formal requirement that racial and ethnic data be collected in clinical trials. By standardizing this as a requirement, appropriate collection of racial and ethnic data and correct reporting of this data would be ensured. Furthermore, areas where there is a lack of diversity with respect to clinical research would be more easily identified and appropriate measures could then be taken to address the disparity.
This analysis demonstrated that the burden of HCV within the African American/Black populations within the United States is not reflected in the diversity of clinical trial participants. The percentage of African Americans observed participating in hepatitis C clinical trials was approximately half the expected amount. Hence, the group of people most significantly affected by this disease is underrepresented in clinical trials created to treat the disease.
Identification of viable treatment options within any population for any disease is dependent on inclusion of that population in the research. Intrinsic factors (genetic, metabolic) and external factors (social, economic, cultural) can potentially impact treatment outcomes. 9, 10, [19] [20] [21] [22] Diverse populations within clinical trials help identify safe and efficacious treatment regimens for diverse populations of men and women. One major barrier to minority participation in clinical research trials is recruitment. Minority populations must be engaged to participate in research in a way that helps alleviate concerns related to trust 23 and those conducting the research must commit to pursuing increased diversity within clinical trials. A lack of minority participation within clinical trials may lead to increased health disparities, even in the setting of new and advanced therapies for treatment of a disease.
A major limitation in our analysis of minority participation in hepatitis C clinical trials was the lack of reporting of racial and ethnic data in the literature. As discussed earlier, it is unknown if this is reflective of a lack of collecting or reporting racial data. Nonetheless, this greatly limited our ability to analyze minority participations within clinical trials. The actual percentage of African Americans/Blacks within the included RCTs may be higher, but due to a lack of reporting of this data, we may be underestimating the population totals.
The comparison of US and European trials is limited by the search criteria and database used for this analysis. African American is a designation not used consistently in Europe. We did use the search term Black, but this term may reflect different populations within the US versus Europe. The database used for identification of clinical trials was PubMed. This clinical research database has a US bias and may not accurately reflect all European trials that met criteria. Finally, there does exist significant heterogeneity among the African American population within the United States and Canada, which is reflected in the Q-value of 670.4. for 38 degrees of freedom (p<0.001). However, this heterogeneity was expected and taken into consideration, because the distribution of African Americans across the United States is far from uniform.
In conclusion, the participation of minorities within hepatitis C clinical trials between 2000 and 2011 in the US and Europe was not consistently reported. Overall, US trials reported race more consistently than European trials, and reporting of race increased after 2005. African Americans were underrepresented within these clinical trials given the burden of Hepatitis C within this population. The importance of race as an internal (genetic, metabolic) and external (social, economic, cultural) factor in disease outcomes is well known, and standardization of collecting and reporting racial/ethnic data may ensure consistent and accurate reporting of racial/ethnic data from clinical trials. Research is needed to better understand reasons for lower enrollment of racially and ethnically diverse populations, and to create ways to improve participation of racially and ethnically diverse populations in clinical trials.
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